Cyclooxygenase-2 (COX-2) catalyzes the oxygenation of arachidonic acid (AA) and endocannabinoid substrates, placing the enzyme at a unique junction between the eicosanoid and endocannabinoid signaling pathways. COX-2 is a sequence homodimer, but the enzyme displays half-of-site reactivity, such that only one monomer of the dimer is active at a given time. Certain rapid reversible, competitive nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to inhibit COX-2 in a substrate-selective manner, with the binding of inhibitor to a single monomer sufficient to inhibit the oxygenation of endocannabinoids but not arachidonic acid. The underlying mechanism responsible for substrate-selective inhibition has remained elusive. We utilized structural and biophysical methods to evaluate flufenamic acid, meclofenamic acid, mefenamic acid, and tolfenamic acid for their ability to act as substrateselective inhibitors. Crystal structures of each drug in complex with human COX-2 revealed that the inhibitor binds within the cyclooxygenase channel in an inverted orientation, with the carboxylate group interacting with Tyr-385 and Ser-530 at the top of the channel. Tryptophan fluorescence quenching, continuous-wave electron spin resonance, and UV-visible spectroscopy demonstrate that flufenamic acid, mefenamic acid, and tolfenamic acid are substrate-selective inhibitors that bind rapidly to COX-2, quench tyrosyl radicals, and reduce higher oxidation states of the heme moiety. Substrate-selective inhibition was attenuated by the addition of the lipid peroxide 15-hydroperoxyeicosatertaenoic acid. Collectively, these studies implicate peroxide tone as an important mechanistic component of substrate-selective inhibition by flufenamic acid, mefenamic acid, and tolfenamic acid.The cyclooxygenases (COX-1 and COX-2) convert arachidonic acid (AA) 2 to prostaglandin H 2 (1). Prostaglandin H 2 is subsequently metabolized by downstream tissue-specific synthases into potent signaling molecules that play fundamental roles in both the regulation of physiological homeostasis as well as in disease states such as inflammation and cancer (2). COX-1 preferentially oxygenates AA, whereas COX-2 efficiently oxygenates a broad spectrum of fatty acid, ester, and amide substrates, including the endocannabinoids 1-arachidonoyl glycerol (1-AG), 2-arachidonoyl glycerol, and anandamide (3-8). 2-Arachidonoyl glycerol and anandamide are widely distributed in mammalian tissues and were the first characterized endogenous ligands for the cannabinoid receptors CB 1 and CB 2 (9). COX-2 oxygenates endocannabinoids using the same catalytic mechanism employed for AA, generating PG-glycerol esters and PG-ethanolamides (10 -12). Endocannabinoid signaling plays a significant role in various physiological processes and has been implicated in pathologies ranging from anxiety and depression, to multiple sclerosis, Parkinson disease, and cancer (13). The unique ability to oxygenate endocannabinoids places COX-2 at a critical junction between the eicosanoid and endocann...